Kymera Therapeutics

Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the pricing of its upsized underwritten public